Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT03986073

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03986073
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03986073. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-01 (actual); primary completion 2020-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
TQ-F3083 capsule 10 mg
Intervention (Drug)
TQ-F3083 capsule 20 mg
Intervention (Drug)
TQ-F3083 blank analog capsule
Intervention (Drug)
TQ-F3083 blank analog capsule
Intervention (Drug)
Linagliptin blank analog tablet
Intervention (Drug)
Linagliptin tablet
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03986073
Content hash
baa41b5110255bacc35a174ee62c72deae8ed80cd2e7851c78e49a6491be1c32